User profiles for "author:D. Eljuga"

Domagoj Eljuga

MD, PhD, Professor, Fellow of EBOPRAS
Verified email at plastsurgacademy.eu
Cited by 172

Organometallic ruthenium (II)-arene complexes with triphenylphosphine amino acid bioconjugates: Synthesis, characterization and biological properties

…, Z Glasovac, LM Tumir, I Piantanida, D Eljuga… - Bioorganic …, 2019 - Elsevier
Abstract (p-Cymene)-ruthenium bioconjugates ML (1) and ML 2 (2), bearing phosphane
ligands substituted with chiral or non-chiral amino acid esters, L, were synthetized and …

[HTML][HTML] Discovery of 'click'1, 2, 3-triazolium salts as potential anticancer drugs

…, MR Stojkovic, I Piantanida, D Eljuga… - Radiology and …, 2016 - sciendo.com
Background. In order to increase the effectiveness of cancer treatment, new compounds with
potential anticancer activities are synthesized and screened. Here we present the screening …

The characterization of two human cervical carcinoma HeLa sublines resistant to cisplatin

M Osmak, D Eljuga - Research in experimental medicine, 1993 - Springer
Human cervical carcinoma HeLa cells were made resistant to cisplatin by one of two
schedules;“acute”(cells repeatedly treated with cisplatin for 1 h in serum-free medium—CA …

[HTML][HTML] Polymorphisms in Survivin (BIRC5 Gene) Are Associated with Age of Onset in Breast Cancer Patients

…, M Sabol, S Levanat, D Trnski, D Eljuga… - Journal of …, 2019 - hindawi.com
Survivin, encoded by BIRC5 gene (baculoviral IAP repeat containing 5), belongs to the
family of inhibitors of apoptosis proteins (IAPs). In mammalian cells it participates in the …

[HTML][HTML] Higher expressions of SHH and AR are associated with a positive receptor status and have impact on survival in a cohort of croatian breast cancer patients

…, Č Tomasović-Lončarić, K Kralik, J Čonkaš, D Eljuga… - Life, 2022 - mdpi.com
Breast cancers (BC) are usually classified into four molecular subtypes according to the
expression of estrogen (ER), progesterone (PR), and human epidermal growth factor 2 …

Three novel BRCA1/BRCA2 mutations in breast/ovarian cancer families in Croatia

…, P Ozretic, D Car, D Eljuga, L Eljuga, D Eljuga - Gene, 2012 - Elsevier
BRCA1 and BRCA2 genes from 167 candidates (145 families) were scanned for mutations.
We identified 14 pathogenic point mutations in 17 candidates, 9 in BRCA1 and 5 in BRCA2 …

Prognostic importance of PAI-1 in node negative breast cancer patients—results after 10 years of follow up

D Eljuga, JJ Razumovic, K Bulic, M Petrovecki… - … -Research and Practice, 2011 - Elsevier
The serine protease urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1)
play key roles in the proteolytic cascade involved in physiological and pathological …

Abdominal wall endometriosis: case report

D Eljuga, P Klarić, I Bolanča, I Grbavac, K Kuna - Acta clinica Croatica, 2012 - hrcak.srce.hr
Sažetak Abdominal wall endometriosis, also known as scar endometrioma, is a rare
condition, in most cases occurring after previous cesarean section or pelvic surgery. The …

[HTML][HTML] Diazenes: modificators of tumor cell resistance to cisplatin

…, J Kosmrlj, M Kvajo, Z Marijanovic, D Eljuga… - Neoplasma, 1999 - sav.sk
Most studies indicate that modulation of glutathione metabolism may be one of the most
promissing means of reversing clinical drug resistance. Five new diazene compounds have …

[PDF][PDF] Biomechanical properties of bones from rats treated with sevelamer

N Drača, A Tikvica, D Eljuga, D Semenski… - Collegium …, 2011 - hrcak.srce.hr
11030 draca.vp Page 1 Coll. Antropol. 35 (2011) 2: 557–563 Original scientific paper
Biomechanical Properties of Bones from Rats Treated with Sevelamer Natasa Dra~a1, Ana …